TITLE

Interstitial Vasculitis -- Interstitial Lung Disease: Case Studies

AUTHOR(S)
Demeter, Stephen L.
PUB. DATE
April 1986
SOURCE
Angiology;Apr1986, Vol. 37 Issue 4, p325
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Six patients with interstitial lung disease were tested in a serial fashion to determine response to medications. All patients had biopsy-proven interstitial lung disease. Exercise testing with measurements of Pa02, PaCO2, and DLCO (the diffusing capacity to carbon monoxide) were made before and after exercise to determine the response to medications. Three patients were treated with corticosteroids and three patients with cytotoxic medications. Results of serial testing of gas transfer correlated with improvement of interstitial lung disease as characterized by resting Pa02, symptoms, and maximal duration of exercise. The value of serial exercise testing is of great help in some, but not all patients. The value of serial testing of patients with interstitial lung disease is discussed.
ACCESSION #
16478312

 

Related Articles

  • Interstitial Lung Disease in Lung Cancer: Separating Disease Progression from Treatment Effects. Danson, Sarah; Blackhall, Fiona; Hulse, Paul; Ranson, Malcolm // Drug Safety;2005, Vol. 28 Issue 2, p103 

    Lung cancer often develops in individuals with pre-existing pulmonary and cardiac pathology. Many of these individuals with pre-existing pathology are also at risk of occupational lung disease. New and worsening symptoms can be secondary to pre-existing pathology, progressive cancer or...

  • Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Mason, Rebecca H.; Foley, Noeleen M.; Branley, Howard M.; Adamali, Huzaifa I.; Hetzel, Martin; Maher, Toby M.; Suntharalingam, Jay // Thorax;Aug2014, Vol. 69 Issue 8, p766 

    Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease of unknown aetiology. We aimed to characterise a UK-wide cohort of patients with PLCH and compare diagnostic and management methods in specialist and nonspecialist centres. 106 cases (53 hospitals) identified....

  • Gefitinib.  // Reactions Weekly;11/6/2010, Issue 1326, p19 

    This article describes a case study involving a 77-year-old woman who developed interstitial lung disease following treatment with gefitinib for lung adenocarcinoma.

  • Antineoplastics.  // Reactions Weekly;4/16/2011, Issue 1347, p10 

    The article describes a case of fatal interstitial lung disease which developed in a 64-year-old man with metastatic gastric cancer during treatment with the antineoplastic FOLFOX-4.

  • Erlotinib/gefitinib.  // Reactions Weekly;10/29/2011, Issue 1375, p15 

    The article describes the clinical cases of 12 men and eight women, aged 55 to 84 years with advanced non-small cell lung cancer, who developed interstitial lung disease after receiving erlotinib or gefitinib.

  • Everolimus/sunitinib/temsirolimus.  // Reactions Weekly;Oct2015, Vol. 1573 Issue 1, p116 

    The article discusses the retrospective study which shows the number of patients who developed interstitial lung disease after receiving everolimus, sunitinib or temsirolimus treatment for metastatic renal cell carcinoma.

  • Gefitinib.  // Reactions Weekly;3/3/2012, Issue 1391, p23 

    The article describes the clinical cases of three patients, diagnosed with stage IV non-small cell lung cancer, who developed interstitial lung disease (ILD) while under gefitinib treatment regimen.

  • Gefitinib.  // Reactions Weekly;3/17/2012, Issue 1393, p22 

    The article describes the case of a 41-year-old woman who developed interstitial lung disease while under gefitinib treatment regimen for stage IV lung adenocarcinoma.

  • Everolirnus.  // Reactions Weekly;7/28/2012, Issue 1412, p21 

    The article describes the clinical cases of seven patients who developed interstitial lung disease (ILD) after receiving everolimus for metastatic renal cell carcinoma.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics